S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91

Celldex Therapeutics Stock Forecast, Price & News

+1.52 (+4.21%)
(As of 12/2/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
305,103 shs
Average Volume
642,345 shs
Market Capitalization
$1.76 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Celldex Therapeutics logo

About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.


See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$7.42 million
Book Value
$5.29 per share


Net Income
$-59.78 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.76 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.20 out of 5 stars

Medical Sector

385th out of 1,391 stocks

Diagnostic Substances Industry

5th out of 25 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

Is Celldex Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celldex Therapeutics stock.
View analyst ratings for Celldex Therapeutics
or view top-rated stocks.

How has Celldex Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLDX stock has increased by 1,752.7% and is now trading at $37.61.
View which stocks have been most impacted by COVID-19

Are investors shorting Celldex Therapeutics?

Celldex Therapeutics saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 3,720,000 shares, an increase of 25.7% from the October 14th total of 2,960,000 shares. Based on an average trading volume of 472,500 shares, the short-interest ratio is currently 7.9 days.
View Celldex Therapeutics' Short Interest

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Celldex Therapeutics

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.09. The biopharmaceutical company earned $0.15 million during the quarter, compared to analyst estimates of $1.70 million. Celldex Therapeutics had a negative net margin of 891.70% and a negative trailing twelve-month return on equity of 22.71%.
View Celldex Therapeutics' earnings history

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Shares of Celldex Therapeutics reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLDX?

5 brokers have issued 1-year price targets for Celldex Therapeutics' stock. Their forecasts range from $35.00 to $68.00. On average, they anticipate Celldex Therapeutics' share price to reach $59.00 in the next twelve months. This suggests a possible upside of 56.9% from the stock's current price.
View analysts' price targets for Celldex Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the following people:
  • Anthony S. Marucci, President, Chief Executive Officer & Director
  • Sam Martin, CFO, Secretary, Treasurer & Senior Vice President
  • Tibor Keler, Chief Scientific Officer & Executive VP
  • Diane C. Young, Chief Medical Officer & Senior Vice President (LinkedIn Profile)
  • Elizabeth Crowley, Chief Product Development Officer & Senior VP

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.74%), Wellington Management Group LLP (4.67%), RA Capital Management L.P. (3.43%), VR Adviser LLC (2.35%), Geode Capital Management LLC (1.70%) and Viking Global Investors LP (1.63%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics

Which major investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Renaissance Technologies LLC, VR Adviser LLC, Allianz Asset Management GmbH, Commodore Capital LP, TSP Capital Management Group LLC, AXA S.A., and Goldman Sachs Group Inc.. Company insiders that have sold Celldex Therapeutics company stock in the last year include Diane C Young, Richard M Wright, and Samuel Bates Martin.
View insider buying and selling activity for Celldex Therapeutics
or view top insider-selling stocks.

Which major investors are buying Celldex Therapeutics stock?

CLDX stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Viking Global Investors LP, Cowen AND Company LLC, BlackRock Inc., Polar Capital Holdings Plc, Wellington Management Group LLP, Sphera Funds Management LTD., and Geode Capital Management LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler.
View insider buying and selling activity for Celldex Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $37.61.

How much money does Celldex Therapeutics make?

Celldex Therapeutics has a market capitalization of $1.76 billion and generates $7.42 million in revenue each year. The biopharmaceutical company earns $-59.78 million in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

Celldex Therapeutics employs 124 workers across the globe.

When was Celldex Therapeutics founded?

Celldex Therapeutics was founded in 1983.

What is Celldex Therapeutics' official website?

The official website for Celldex Therapeutics is www.celldex.com.

Where are Celldex Therapeutics' headquarters?

Celldex Therapeutics is headquartered at 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at (908) 200-7500, via email at [email protected], or via fax at 908-454-1911.

This page was last updated on 12/3/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.